Advertisement

Biological Trace Element Research

, Volume 155, Issue 2, pp 295–300 | Cite as

Bis(oxalato)dioxovanadate(V) and Bis(oxalato)oxoperoxo-vanadate(V) Complexes: Spectroscopic Characterization and Biological Activity

  • Ignacio E. León
  • Susana B. Etcheverry
  • Beatriz S. Parajón-Costa
  • Enrique J. BaranEmail author
Article

Abstract

Two structurally related vanadium(V) complexes, K3[VO2(C2O4)2]·3H2O and K3[VO(O2)(C2O4)2]·1/2H2O, were thoroughly characterized by infrared, Raman, and electronic spectroscopies. The effect of both complexes on the viability of the human MG-63 osteosarcoma cells was tested using the MTT assay. The monoperoxo complex shows a very strong antiproliferative activity (at 100-μM concentration, this complex diminished the cell viability ca. 80 %), whereas the dioxo complex was inactive.

Keywords

Vanadium(V) Bis(oxalato) complexes Peroxo ligand Vibrational spectra Electronic spectra Osteosarcoma cells in culture 

Notes

Acknowledgements

This work was supported by the Agencia Nacional de Promoción Cientifica y Tecnológica-ANPCyT (PICT 2218), by the Consejo Nacional de Investigaciones Científicas y Técnicas-CONICET (PIP 1125), and by the Universidad Nacional de La Plata (X-560 and X-554). IEL is a fellow from ANPCyT, and SBE and BSPC are members of the Research Career from CONICET.

References

  1. 1.
    Rehder D (2008) Bioinorganic vanadium chemistry. Wiley, ChichesterCrossRefGoogle Scholar
  2. 2.
    Barrio DA, Etcheverry SB (2010) Potential use of vanadium compounds in therapeutics. Curr Med Chem 17:3632–3642PubMedCrossRefGoogle Scholar
  3. 3.
    Rehder D (2012) The potentiality of vanadium in medicinal applications. Future Med Chem 4:1823–1837PubMedCrossRefGoogle Scholar
  4. 4.
    Thompson KH, McNeill JH, Orvig C (1999) Vanadium-containing insulin drugs. In: Clarke MJ, Sadler PJ (eds) Metallopharmaceuticals II. Springer, Berlin, pp 139–158CrossRefGoogle Scholar
  5. 5.
    Thompson KH, Orvig C (2006) Vanadium in diabetes: 100 years from phase 0 to phase I. J Inorg Biochem 100:1925–1935PubMedCrossRefGoogle Scholar
  6. 6.
    Levina A, Lay PA (2011) Metal-based anti-diabetic drugs: advances and challenges. Dalton Trans 40:11675–11686PubMedCrossRefGoogle Scholar
  7. 7.
    Barrio DA, Costa-Pessoa J, Etcheverry SB (2012) Diabetes mellitus y vanadio. In: Gambino D, Moreno V, Navarro M (eds) Aplicaciones de los compuestos metálicos en medicina. EAE-LAP Lambert Academic Publishing GmbH & Co KG, Saarbrücken, pp 227–322Google Scholar
  8. 8.
    Evangelou AM (2002) Vanadium in cancer treatment. Crit Rev Oncol Hematol 42:249–265PubMedCrossRefGoogle Scholar
  9. 9.
    Djordjevic C (1995) Antitumor activity of vanadium compounds. In: Sigel H, Sigel A (eds) Metal ions in biological systems, vol. 31: vanadium and its role in life. Marcel Dekker, New York, pp 595–616Google Scholar
  10. 10.
    D’Cruz OJ, Uckun FM (2002) Metvan: a novel oxovanadium(IV) complex with broad spectrum anticancer activity. Expert Opin Invest Drugs 11:1829–1836CrossRefGoogle Scholar
  11. 11.
    Benítez J, Guggeri L, Tomaz I, Arrambide G, Navarro M, Costa Pessoa J, Garat B, Gambino D (2009) Design of vanadium mixed-ligand complexes as potential anti-protozoa agents. J Inorg Biochem 103:609–616PubMedCrossRefGoogle Scholar
  12. 12.
    Benítez J, Guggeri L, Tomaz L, Costa Pessoa J, Moreno V, Lorenzo J, Avilés FX, Garat B, Gambino D (2009) A novel vanadyl complex with a polypyridyl DNA intercalator as ligand: a potential anti-protozoa and anti-tumor agent. J Inorg Biochem 103:1386–1394PubMedCrossRefGoogle Scholar
  13. 13.
    Maiti A, Ghosh S (1989) Synthesis and reactivity of the oxovanadium(IV) complexes of two NO donors and potentiation of the antituberculosis activity of them on chelation to metal ions. Part IV. J Inorg Biochem 36:131–139PubMedCrossRefGoogle Scholar
  14. 14.
    Baran EJ (2003) Model studies related to vanadium biochemistry: recent advances and perspectives. J Braz Chem Soc 14:878–888CrossRefGoogle Scholar
  15. 15.
    Baran EJ (2008) Vanadium detoxification: chemical and biochemical aspects. Chem Biodivers 5:1475–1484PubMedCrossRefGoogle Scholar
  16. 16.
    Nielsen FH (1995) Vanadium in mammalian physiology and nutrition. In: Sigel H, Sigel A (eds) Metal ions in biological systems, vol. 31: vanadium and its role in life. Marcel Dekker, New York, pp 543–573Google Scholar
  17. 17.
    Stomberg R (1986) The crystal structures of potassium bis(oxalate)oxoperoxovanadate(V) hemihydrate, K3[VO(O2)(C2O4)2].1/2H2O, and potassium bis(oxalato)dioxovanadate(V) trihydrate, K3[VO2(C2O4)2].3H2O. Acta Chem Scand A40:166–178Google Scholar
  18. 18.
    Schwendt P, Petrovič P (1980) Oxo-peroxo Komplexe des Vanadiums(V). Z Anorg Allg Chem 466:232–236CrossRefGoogle Scholar
  19. 19.
    Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65:55–63CrossRefGoogle Scholar
  20. 20.
    Tatiersky J, Pacigová S, Sivák M, Schwendt P (2009) Monoperoxidovanadium(V) complexes: synthesis, structure and solution properties. J Argent Chem Soc 97:181–198Google Scholar
  21. 21.
    Drew FW, Einstein FWB, Gransden SE (1974) The crystal structure of tripotassium bis(oxalate)dioxovanadate(V) trihydrate. Can J Chem 52:2184–2189CrossRefGoogle Scholar
  22. 22.
    Siebert H (1966) Anwendungen der Schwingungsspektroskopie in der Anorganischen Chemie. Springer, BerlinCrossRefGoogle Scholar
  23. 23.
    Libowitzky E (1990) Correlation of O-H stretching frequencies and O-HO hydrogen bond lengths in minerals. Monatsh Chem 130:1047–1059CrossRefGoogle Scholar
  24. 24.
    Taguchi K, Isobe K, Nakamura Y, Kawaguchi S (1978) Cis-dioxo vanadium(V) and mixed-valence divanadium(IV, V) complexes containing β-diketonate and hetrocyclic nitrogen-base ligands. Bull Chem Soc Jpn 51:2030–2035CrossRefGoogle Scholar
  25. 25.
    D’Antonio MC, Mancilla N, Wladimirsky A, Palacios D, González-Baró AC, Baran EJ (2010) Vibrational spectra of magnesium oxalates. Vibrat Spectrosc 53:218–221CrossRefGoogle Scholar
  26. 26.
    Wladimirsky A, Palacios D, D’Antonio MC, González-Baró AC, Baran EJ (2011) Vibrational spectra of the α-MIIC2O4·2H2O oxalato complexes, with MII = Co, Ni, Zn. J Argent Chem Soc 98:71–77Google Scholar
  27. 27.
    Hind AR, Bhargava SK, van Bronswijk W, Grocott SC, Eyer SL (1998) On the aqueous vibrational spectra of alkali metal oxalates. Appl Spectr 52:683–691CrossRefGoogle Scholar
  28. 28.
    Ross SD (1972) Inorganic infrared and Raman spectra. McGraw-Hill, LondonGoogle Scholar
  29. 29.
    Müller A, Baran EJ, Carter RO (1976) Vibrational spectra of oxo-, thio-, and selenometallates of transition elements in the solid state. Struct Bond 26:81–139CrossRefGoogle Scholar
  30. 30.
    Griffith WP (1964) Studies on transition-metal peroxy-complexes.III. Peroxy-complexes of groups IVA, VA and VIA. J Chem Soc 5248–5253Google Scholar
  31. 31.
    Müller A, Diemann E, Jorgensen CK (1973) Electronic spectra of tetrahedral oxo-, thio and seleno complexes formed by elements of the beginning of the transition groups. Struct Bond 14:23–47CrossRefGoogle Scholar
  32. 32.
    Bishayee A, Wagharay A, Patel MA, Chatterjee M (2010) Vanadium in the detection, prevention and treatment of cancer: the in vivo evidence. Cancer Lett 294:1–12PubMedCrossRefGoogle Scholar
  33. 33.
    Djordjevic C, Wampler GL (1985) Antitumor activity and toxicity of peroxo heteroligand vanadates(V) in relation to biochemistry of vanadium. J Inorg Biochem 28:51–55CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Ignacio E. León
    • 1
    • 2
  • Susana B. Etcheverry
    • 1
    • 2
  • Beatriz S. Parajón-Costa
    • 2
  • Enrique J. Baran
    • 2
    Email author
  1. 1.Cátedra de Bioquímica Patológica, Facultad de Ciencias ExactasUniversidad Nacional de La PlataLa PlataArgentina
  2. 2.Centro de Química Inorgánica (CEQUINOR/CONICET,UNLP), Facultad de Ciencias ExactasUniversidad Nacional de La PlataLa PlataArgentina

Personalised recommendations